Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00137813
Status:
COMPLETED
Last Update Posted:
2018-11-01
First Post:
2005-08-29
Brief Title:
Avastin and Taxotere for Esophagogastric Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
Phase II Study of Bevacizumab and Docetaxel AvaTax in Metastatic Esophagogastric Cancer
Status:
COMPLETED
Status Verified Date:
2018-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine what effects good and bad bevacizumab Avastin and docetaxel Taxotere used in combination have on metastatic gastric and esophageal cancer
Detailed Description:
Bevacizumab will be administered intravenously in an outpatient clinic once a week every other week Docetaxel will also be administered intravenously in the outpatient clinic once a week for three out of four weeks Blood tests and vital signs will be performed weekly
After the first eight weeks of therapy a CT scan will be performed to determine and assess the progress of the disease If therapy is continued radiological procedures will be performed at week 16 and every 8 weeks thereafter
Treatment will be given for a minimum of 8 weeks as long as the patient does not experience unacceptable side effects Chemotherapy will continue for a year and a half as long as the cancer is responding and there are no unacceptable side effects
After the first eight weeks of therapy a CT scan will be performed to determine and assess the progress of the disease If therapy is continued radiological procedures will be performed at week 16 and every 8 weeks thereafter
Treatment will be given for a minimum of 8 weeks as long as the patient does not experience unacceptable side effects Chemotherapy will continue for a year and a half as long as the cancer is responding and there are no unacceptable side effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None